Summary

• Page properties (1 modified, 0 added, 0 removed)
• Attachments (0 modified, 0 added, 1 removed)
  • tridimensional.png
• Objects (1 modified, 0 added, 2 removed)
  • Collaboratory.Apps.Collab.Code.CollabClass[0]
  • XWiki.XWikiRights[3]
  • XWiki.XWikiRights[4]

Details

Page properties

Content

...	...	@@ -2,9 +2,10 @@
2	2	(((
3	3	(% class="container" %)
4	4	(((
5		-= //A new tridimensional diagnostic framework for CNS diseases// =
	5	+= **Neurodiagnoses**
	6	+//A new tridimensional diagnostic framework for CNS conditions// =
6	6
7		-This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
	8	+This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8	8	We aim to create a structured, interpretable, and scalable diagnostic tool.
9	9	)))
10	10	)))
...	...	@@ -15,18 +15,14 @@
15	15	(((
16	16	= What is this about and what can I find here? =
17	17
18		-== **Overview** ==
	19	+==== **Overview** ====
19	19
20		-The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on:
	21	+The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on:
21	21
22		-* **Axis 1**: Etiology (genetic or other causes of diseases).
23		-* **Axis 2**: Molecular Markers (biomarkers).
	23	+* **Axis 1**: Etiology (genetic/sporadic and environmental factors).
	24	+* **Axis 2**: Molecular Markers (biomarkers and proteinopathies).
24	24	* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25	25
26		-
27		-[[For instance, neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
28		-
29		-
30	30	This methodology enables:
31	31
32	32	* Greater precision in diagnosis.
...	...	@@ -33,16 +33,14 @@
33	33	* Integration of incomplete datasets using AI-driven probabilistic modeling.
34	34	* Stratification of patients for personalized treatment.
35	35
36		-== **The case of neurodegenerative diseases** ==
	33	+==== **Diagnostic Axes** ====
37	37
38		-There have been described these 3 diagnostic axes:
39		-
40	40	* (((
41	41	**Axis 1: Etiology**
42	42
43	43	* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
44	44	* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
45		-* //Tests//: Genetic testing, lifestyle, and cardiovascular screening.
	40	+* //Tests//: Genetic testing, lifestyle and cardiovascular screening.
46	46	)))
47	47	* (((
48	48	**Axis 2: Molecular Markers**
...	...	@@ -59,11 +59,28 @@
59	59	* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
60	60	)))
61	61
62		-== **Applications** ==
	57	+==== **Case Studies** ====
63	63
	59	+1. (((
	60	+**Sporadic Alzheimer’s Disease**:
	61	+
	62	+* Axis 1: Sporadic (ApoE4, poor sleep habits).
	63	+* Axis 2: Amyloid-beta plaques, elevated NFL.
	64	+* Axis 3: Right hippocampus atrophy (visual memory loss).
	65	+)))
	66	+1. (((
	67	+**Genetic Parkinson’s Disease**:
	68	+
	69	+* Axis 1: Genetic (LRRK2 mutation).
	70	+* Axis 2: Alpha-synuclein aggregation.
	71	+* Axis 3: Substantia nigra degeneration (motor dysfunction).
	72	+)))
	73	+
	74	+==== **Applications** ====
	75	+
64	64	This system enhances:
65	65
66		-* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
	78	+* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials.
67	67	* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
68	68
69	69	== Who has access? ==
...	...	@@ -70,13 +70,13 @@
70	70
71	71	We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
72	72
73		-== How to Contribute ==
	85	+== How to Contribute: ==
74	74
75	75	* Access the `/docs` folder for guidelines.
76	76	* Use `/code` for the latest AI pipelines.
77	77	* Share feedback and ideas in the wiki discussion pages.
78	78
79		-== Key Objectives ==
	91	+== Key Objectives: ==
80	80
81	81	* Develop interpretable AI models for diagnosis and progression tracking.
82	82	* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
...	...	@@ -90,14 +90,11 @@
90	90	{{toc/}}
91	91	{{/box}}
92	92
93		-== Main contents ==
	105	+== Main contents: ==
94	94
95	95	* `/docs`: Documentation and contribution guidelines.
96	96	* `/code`: Machine learning pipelines and scripts.
97	97	* `/data`: Sample datasets for testing.
98	98	* `/outputs`: Generated models, visualizations, and reports.
99		-* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]]
100		-* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]]
101		-* [[to-do-list>>to-do-list]]
102	102	)))
103	103	)))

tridimensional.png

Author

...	...	@@ -1,1 +1,0 @@
1		-XWiki.manuelmenendez

Size

...	...	@@ -1,1 +1,0 @@
1		-149.8 KB

Content

Collaboratory.Apps.Collab.Code.CollabClass[0]

Public

...	...	@@ -1,1 +1,1 @@
1		-Yes
	1	+No

XWiki.XWikiRights[3]

Allow/Deny

...	...	@@ -1,1 +1,0 @@
1		-Allow

Levels

...	...	@@ -1,1 +1,0 @@
1		-view

Users

...	...	@@ -1,1 +1,0 @@
1		-XWiki.XWikiGuest

XWiki.XWikiRights[4]

Allow/Deny

...	...	@@ -1,1 +1,0 @@
1		-Allow

Groups

...	...	@@ -1,1 +1,0 @@
1		-XWiki.XWikiAllGroup

Levels

...	...	@@ -1,1 +1,0 @@
1		-view